Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that inositol hexaphosphate significantly reduced hearing threshold shifts and outer hair cell loss in various sensorineural hearing loss mouse models, suggesting potential for otoprotective use.

This study found that in SAMP8 mice, phenotypic changes in outer hair cells or the stria vascularis, possibly due to oxidative deficiencies, may predict variability in age-related hearing loss before outer hair cell loss occurs.

This study highlighted the significant role of VSM in cochlear aging, suggesting that changes in its structure and composition may contribute to the development of various pathologies, including congenital hearing disorders, while also identifying the need for further research on VCM-associated molecules.

In this study, researchers found that cochlear hair cell function declined with age in CBA/CaJ mice starting at 10 months, before detectable hearing loss, and was marked by a decrease in cell size and BK channel currents, without effect on MET currents.

This review explores the mechanisms of hair cell death due to factors like noise, ototoxic drugs, and aging and reports no conclusive clinical results; ongoing research may eventually enable preventive treatments for hearing loss.

This study found that allergic rhinitis is linked to a higher risk of developing androgenetic alopecia, while second-generation H1-antihistamine use was associated with a reduced risk, especially in younger patients.

This study investigated AHR signaling's role in skin biology and reported that novel AHR ligands may help restore keratinocyte function and reduce inflammation in skin diseases, suggesting their potential as therapeutic agents.

This study identified a compound heterozygous mutation in a hairless rhesus macaque, which was associated with skin abnormalities similar to those in hairless mice and humans with APL.

This study identified a new genetic locus, ahl4, on distal Chromosome 10 that contributes to the early-onset, severe hearing loss in A/J mice compared to B6 mice.

This study reports that AhR pathway expression is significantly reduced in lymphocytes of alopecia areata patients, suggesting its potential as a diagnostic marker and therapeutic target.

This study found that the ARL15 gene affects adipocyte differentiation and adiponectin secretion, and suggests that ARL15 haploinsufficiency may predispose individuals to lipodystrophy.

This study reports the first case of atrichia with papular lesions in a Taiwanese family without a detectable mutation in the HR gene.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

Researchers found a new mutation in the HR gene causing hair loss and skin bumps in a Pakistani family.

Reduced AhR signaling in HS tunnels leads to persistent inflammation and microbial imbalance.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

This article discusses the role of HR gene mutations in differentiating atrichia with papular lesions from alopecia universalis, but presents no new experimental results.

In this study, researchers identified a novel and two previously reported pathogenic mutations in the HR gene associated with atrichia with papular lesions in five Pakistani families.

This study found a recurrent nonsense mutation in the HR gene linked to atrichia with papular lesions in two Kashmiri families, suggesting whole exome sequencing as an efficient method for diagnosis and genetic counseling.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

This study identified enzymes responsible for regulating androgen action in the human prostate, suggesting that inhibiting AKR1C2 or RL-HSD may have therapeutic potential in androgen insufficiency or benign prostatic hyperplasia, respectively.

This study demonstrates that miniaturized hair follicles in female pattern hair loss overexpress nuclear aryl hydrocarbon receptors, suggesting a potential role for environmental pollutants in this condition.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

This study observed four consanguineous families with congenital atrichia with papular lesions and identified three novel mutations in the hairless gene, which may contribute to the disorder.

Genetic testing for hairless gene mutations is crucial to correctly diagnose and treat atrichia with papular lesions.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.